Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2001-02-01
2002-12-31
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S497000, C435S360000, C435S357000
Reexamination Certificate
active
06500449
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the delivery of biologically active molecules to the eye. The invention relates more particularly to encapsulated cells, their preparation and use to deliver in vivo effective amounts of biologically active molecules. The invention is particularly suited for the treatment of photoreceptor degeneration retinopathies or cancers.
BACKGROUND AND PRIOR ART
There are many diseases of the eyes or ocular diseases which affect vision. Some of these diseases include diseases of the conjunctiva and cornea which can produce loss of visual acuity, pain and discharge, cataracts resulting in blurred vision, glare altered color perception and monocular diplopia, uveal diseases resulting in photophobia, ocular discomfort and visual blurring, retinal diseases resulting in distortion of straight lines (metamorphopsia), loss of central acuity and visual field abnormalities and diseases of Bruch's membrane, which may lead to age-related macular degeneration.
Among numerous forms of human retinopathies, age-related macular degeneration (hereinafter referred to as AMD) is the leading cause of severe vision loss in the elderly and affects between 6.4% (New Zealand)(19) and 6.9-11.4% (U.S.A.) (20, 21) of people beyond the age of 65. AMD is a heterogeneous group of retinal degenerations which is associated with alterations of retinal pigment epithelium (RPE) cells.
In the past transplantation of rod-enriched adult photoreceptor cell populations that may protect the macula from secondary degeneration in rod-cone retinitis pigmentosa affected patients was generally the therapy of choice for retinal degenerations, including AMD. However, the photoreceptors that were to be transplanted usually came from adult or embryonic human photoreceptors collected post-mortem. These photoreceptors can thus be infected by a diversity of viruses including the hepatitis virus, cytomegalovirus, and human immuno-deficiency virus as well as other pathogens such as prions that may remain undetectable prior to transplantation. Additionally, these cells may trigger a strong immune response in the host, leading to the destruction of the graft and/or to inflammatory autoimmune reactions.
Moreover, oculo gene therapy protocols which relied on the basis of cell transfection, viral cell infection, or cell transplantation were also known in this art. However one problem with the known gene therapy protocols was that adverse immunological side effects occurred. These adverse side effects, in some instances, could lead to anaphylactic shock, endangering the patient.
Among various protocols which have been designed to transfer therapeutically important genes to a target tissue, the transplantation of genetically engineered cells has become particularly promising in recent years. To protect allogeneic or xenogeneic grafts from immune rejection, cells have been successfully microencapsulated with non-degradable biocompatible polymers and used for the experimental treatment of several disorders such as type I diabetes mellitus (1-5), dwarfism (6), hemophilia B (7), anemia (8), chronic pain (9, 10), amyotrophic lateral sclerosis (11), as well as Parkinson's, Huntington's, and Alzheimer's diseases (12-18). However, none of these cited references taught a method for treating ocular diseases.
Thus, it is an object of the present invention to provide genetically modified cells which stably produce therapeutic factors suitable for treating ocular disorders.
It is another object of the present invention to provide methods of encapsulating such genetically modified cells, in such a way that the cells remain viable and produce effective amounts of the biologically active agent(s) in the eye, more particularly in the retina.
It is another object of the present invention to provide a method for implanting in vivo these devices (encapsulated cells), and the effective release and treatment of ocular disorders in vivo.
It is another object of the present invention to provide ocular compositions that can be surgically retrieved from the ocular globes, for instance, in case of an occurrence of adverse side effects.
It is yet another object of the present invention to provide compositions and methods to deliver biologically active molecules to the eye to treat ocular disorders that are bacteriological and virological safe.
It is yet another object of the present invention to provide genetically engineered cell lines that can be systematically tested for any kind of pathogens before they are encapsulated and transplanted into human eyes.
It is yet another object of the present invention to provide a therapeutic method to promote the survival of photoreceptor cells in degenerating retinas of mammals in order to treat retinal degenerations, as well as treating mammals that have retinitis pigmentosa or age-related macular degeneration.
These and other objects are achieved by the present invention as evidenced by the summary of the invention, description of the preferred embodiments and the claims.
SUMMARY OF THE INVENTION
In one of the method aspects, the present invention provides a method for delivering a polypeptide to an ocular cell of a subject in vivo said method comprising the step of:
(a) implanting in an eye of said subject a composition comprising cells which produce said polypeptide wherein said cells are encapsulated.
In another method aspect, the present invention provides a method for reducing an ocular disease comprising the step of:
(a) administering to a subject in need of said treatment a composition comprising encapsulated cells wherein said cells produce a biologically active polypeptide for reducing said ocular disease.
In a composition aspect, the present invention provides a composition comprising encapsulated cells which produce an endostatin or a fibroblast growth factor polypeptide.
REFERENCES:
patent: 5374616 (1994-12-01), Spiegel et al.
patent: 5904144 (1999-05-01), Hammang et al.
patent: 6299895 (2001-10-01), Hammang et al.
patent: WO 97/34586 (1997-09-01), None
Serguera, C. et al., “Control of Erythropoietin Secretion by Doxycycline or Mifepristone in Mice Bearing Polymer-Encapsulated Engineered Cells”,Human Gene Therapy, 10:375-383 (Feb. 10, 1999).
Uludag, H. et al., “Technology of mammalian cell Encapsulation”,Advanced Drug Delivery Review, 20:29-64 (2000).
Abitbol Marc
Bonnel Sébastian
Bossard Carine
Honiger Jiri
Menasche Maurice
Lilling Herbert J.
Merchant & Gould P.C.
Patten Patricia D
Universite de Paris V Rene-Descartes
LandOfFree
Intraocular transplantation of encapsulated cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intraocular transplantation of encapsulated cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intraocular transplantation of encapsulated cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2923558